Doctor profile · Federal record
Dr. John Wallmark, M.D.
Hematology & Oncology Physician (CMS: Hematology/Oncology) · Rockville, MD
- NPI 1689755365
- Accepts Medicare
- MIPS 92.6 / 100 · 2023
- 34 yrs in practice
- Male
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
9707 Medical Center Dr, Suite 300
Rockville, MD 208503348
(301) 424-6231
fax (301) 294-4648
Credentials & registration
- NPI registered
- October 2006 — 20 yrs on file
- Profile last updated
- August 1, 2012
- Year of graduation
- 1992 — 34 yrs since
- Specialty taxonomy
- 207RH0003X — NUCC code
- State license (1)
- Maryland #D0053177
- Medicaid
- MD #40453510
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1689755365. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
138,279
Distinct HCPCS
10
Medicare allowed
$1,933,543
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
J1439 |
Injection, ferric carboxymaltose, 1 mg | 27,000 | 23 | $1 | |
J0881 |
Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 21,360 | 33 | $3 | |
J9025 |
Injection, azacitidine, 1 mg | 17,200 | 13 | $0 | |
J0185 |
Injection, aprepitant, 1 mg | 15,600 | 36 | $2 | |
J9144 |
Injection, daratumumab, 10 mg and hyaluronidase-fihj | 12,240 | 17 | $47 | |
J9267 |
Injection, paclitaxel, 1 mg | 9,780 | 15 | $0 | |
J9271 |
Injection, pembrolizumab, 1 mg | 8,200 | 20 | $54 | |
J0897 |
Injection, denosumab, 1 mg | 6,300 | 43 | $23 | |
J1568 |
Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 2,860 | 20 | $42 | |
J1100 |
Injection, dexamethasone sodium phosphate, 1 mg | 2,122 | 44 | $0 |
In context: peer comparison
Among 4 peers in Rockville Hematology & Oncology Physician, average services per provider: 1,992. This provider delivers 69× the peer median.Open Payments
Industry payments received
All-time total
$2,630
Transactions
58
Manufacturers
15
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | 14 | $1,064.14 | |
| Daiichi Sankyo INC. | 5 | $197.85 | |
| Merck Sharp & Dohme LLC | 6 | $162.74 | |
| GlaxoSmithKline, LLC. | 4 | $120.39 | |
| Abbvie INC. | 4 | $117.28 | |
| Intera Oncology, INC | 1 | $114.21 | |
| Takeda Pharmaceuticals U.S.A., INC. | 4 | $105.01 | |
| AstraZeneca Pharmaceuticals Lp | 3 | $95.87 | |
| Gilead Sciences, INC. | 3 | $72.28 | |
| Pfizer INC. | 3 | $70.83 | |
| E.R. Squibb & Sons, L.L.C. | 3 | $66.89 | |
| Regeneron Healthcare Solutions, INC. | 2 | $61.42 | |
| Taiho Oncology, INC. | 2 | $49.75 | |
| Genentech USA, INC. | 2 | $48.02 | |
| Janssen Biotech, INC. | 2 | $45.55 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
560
Patients
92
Total drug cost
$1,236,282
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Letrozole | Generic | 166 | 51 | $4,901 |
| Xarelto (Rivaroxaban) | Brand | 77 | 21 | $87,109 |
| Anastrozole | Generic | 60 | 20 | $1,986 |
| Warfarin Sodium | Generic | 38 | 0 | $592 |
| Acyclovir | Generic | 33 | 0 | $678 |
| Verzenio (Abemaciclib) | Brand | 33 | 0 | $500,922 |
| Dexamethasone | Generic | 24 | 0 | $441 |
| Ninlaro (Ixazomib Citrate) | Brand | 18 | 0 | $224,914 |
| Exemestane | Generic | 17 | 0 | $3,897 |
| Prednisone | Generic | 17 | 0 | $88 |
Hospital affiliations
Frequently asked questions
What is Dr. John Wallmark's medical specialty?
Dr. John Wallmark practices Hematology & Oncology Physician in Rockville, MD.
Where does Dr. John Wallmark practice?
Dr. John Wallmark practices at 9707 Medical Center Dr, Rockville, MD 208503348. Office phone: 3014246231.
What is Dr. John Wallmark's NPI?
Dr. John Wallmark's National Provider Identifier (NPI) is 1689755365, issued by NPPES.
Does Dr. John Wallmark accept Medicare assignment?
Yes. Dr. John Wallmark accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. John Wallmark commonly perform?
Top Medicare-reported procedures in 2023: Injection, ferric carboxymaltose, 1 mg (HCPCS J1439); Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS J0881); Injection, azacitidine, 1 mg (HCPCS J9025). Source: CMS Medicare Physician & Other Practitioners file.